We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Danaher's Diagnostics Unit Sustain Growth Amid Lower Sales in China?
Read MoreHide Full Article
Key Takeaways
Diagnostics core revenues rose 2% year over year in Q2 2025.
Beckman Coulter Diagnostics grew at high single digits outside China.
Molecular diagnostics recovery boosted by non-respiratory test demand.
Danaher Corporation’s (DHR - Free Report) Diagnostics segment continues to contribute steadily to its overall performance. The segment’s core revenues increased 2% on a year-over-year basis in the second quarter of 2025.
Solid momentum in the clinical diagnostics businesses, led by growth in the Beckman Colter Diagnostics unit, has been buoying the segment’s performance. In the second quarter, core revenues from the clinical diagnostics businesses rose in low single digits. In the quarter, Beckman Coulter Diagnostics unit delivered high single-digit core revenue growth outside China. This marks its fourth consecutive quarter of achieving mid-single-digit or higher growth driven by rising demand for products like DxC 500i Clinical Analyzer and DxI 9000 Access Immunoassay Analyzer.
Recovery in the molecular diagnostics business, driven by an increase in demand for non-respiratory disease tests, has been supporting the performance of the Diagnostics segment as well. However, lower sales in China, owing to volume-based procurement program and healthcare reimbursement changes, are concerning for the segment.
In the quarters ahead, Danaher’s Diagnostics segment is expected to balance these headwinds with continued product innovation and by offering a wider variety of new diagnostic tests. While challenges in China may persist, steady international growth and rising demand for advanced diagnostic solutions position the segment to remain a resilient contributor to the company’s overall performance. For 2025, Danaher anticipates core revenues from the Diagnostics segment to be flat to increase in low single-digits on a year-over-year basis.
Segment Snapshot of DHR's Peers
Among its major peers, Labcorp Holdings Inc.’s (LH - Free Report) Biopharma Laboratory Services segment generated net sales of $784.8 million in the second quarter of 2025, up 11% year over year. This was driven by Labcorp’s strong drug development capabilities and scientific expertise. Labcorp derived 22.1% of its total revenues from this segment during the quarter.
CVS Health Corporation’s (CVS - Free Report) Health Services segment reported net sales of $46.5 billion in the second quarter of 2025, up 10.2% year over year. CVS Health generated 47% of its total sales from this segment in the quarter. Favorable pharmacy drug mix and brand inflation aided CVS Health’s segment’s results in the second quarter.
Price Performance, Valuation and Estimates
Shares of Danaher have lost 30.5% in the past year compared with the industry’s decline of 18%.
Image Source: Zacks Investment Research
From a valuation standpoint, DHR is trading at a forward price-to-earnings ratio of 23.41X, above the industry’s average of 15.05X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DHR’s 2025 earnings has increased 0.9% over the past 60 days.
Image: Bigstock
Can Danaher's Diagnostics Unit Sustain Growth Amid Lower Sales in China?
Key Takeaways
Danaher Corporation’s (DHR - Free Report) Diagnostics segment continues to contribute steadily to its overall performance. The segment’s core revenues increased 2% on a year-over-year basis in the second quarter of 2025.
Solid momentum in the clinical diagnostics businesses, led by growth in the Beckman Colter Diagnostics unit, has been buoying the segment’s performance. In the second quarter, core revenues from the clinical diagnostics businesses rose in low single digits. In the quarter, Beckman Coulter Diagnostics unit delivered high single-digit core revenue growth outside China. This marks its fourth consecutive quarter of achieving mid-single-digit or higher growth driven by rising demand for products like DxC 500i Clinical Analyzer and DxI 9000 Access Immunoassay Analyzer.
Recovery in the molecular diagnostics business, driven by an increase in demand for non-respiratory disease tests, has been supporting the performance of the Diagnostics segment as well. However, lower sales in China, owing to volume-based procurement program and healthcare reimbursement changes, are concerning for the segment.
In the quarters ahead, Danaher’s Diagnostics segment is expected to balance these headwinds with continued product innovation and by offering a wider variety of new diagnostic tests. While challenges in China may persist, steady international growth and rising demand for advanced diagnostic solutions position the segment to remain a resilient contributor to the company’s overall performance. For 2025, Danaher anticipates core revenues from the Diagnostics segment to be flat to increase in low single-digits on a year-over-year basis.
Segment Snapshot of DHR's Peers
Among its major peers, Labcorp Holdings Inc.’s (LH - Free Report) Biopharma Laboratory Services segment generated net sales of $784.8 million in the second quarter of 2025, up 11% year over year. This was driven by Labcorp’s strong drug development capabilities and scientific expertise. Labcorp derived 22.1% of its total revenues from this segment during the quarter.
CVS Health Corporation’s (CVS - Free Report) Health Services segment reported net sales of $46.5 billion in the second quarter of 2025, up 10.2% year over year. CVS Health generated 47% of its total sales from this segment in the quarter. Favorable pharmacy drug mix and brand inflation aided CVS Health’s segment’s results in the second quarter.
Price Performance, Valuation and Estimates
Shares of Danaher have lost 30.5% in the past year compared with the industry’s decline of 18%.
Image Source: Zacks Investment Research
From a valuation standpoint, DHR is trading at a forward price-to-earnings ratio of 23.41X, above the industry’s average of 15.05X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DHR’s 2025 earnings has increased 0.9% over the past 60 days.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.